Celecoxib to prevent restenosis--results from the COREA-TAXUS trial.
Celecoxib inhibits Akt, which is stimulated during restenosis. Cell and animal studies showed that celecoxib inhibited Akt stimulation and restenosis. Recently, the COREA-TAXUS (Effect of Celecoxib on Restenosis after Coronary Angioplasty with Taxus stent) trial was performed in subjects with angina or a positive-stress test receiving paclitaxel-eluting stents. The primary end point at 6 months was the in-stent, late luminal loss, which was 0.49 mm in the celecoxib-treated group; less than the 0.75 mm in the group not treated with celecoxib. The rate of revascularisation of the target lesion was lower in celecoxib-treated subjects (5%) than in the untreated subjects (15%). In conclusion, this is an excellent demonstration of translating a mechanism of action of a drug into a clinical use.
Doggrell
Sheila A
SA
RMIT University, Discipline of Pharmaceutical Sciences, School of Medical Sciences, Bundoora, Victoria 3083, Australia. sheila.doggrell@bigpond.com
D000328:Adult; D000068579:Celecoxib; D023903:Coronary Restenosis / Q000188:drug therapy / Q000517:prevention & control*; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D011720:Pyrazoles / Q000592:standards* / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000639:trends*; D013449:Sulfonamides / Q000592:standards* / Q000627:therapeutic use*
D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib